Vemurafenib [918504-65-1]
Cat# HY-12057-1ml
Size : 10mM/1mL
Brand : MedChemExpress
Vémurafénib (PLX4032) est un inhibiteurde la B-RAF kinase qui est puissant, sélectif et de première classe, avec la IC50s de 31 et 48 nM pour RAFV600E et c-RAF-1, respectivement. Vémurafénib induit une autophagie cellulaire.
Vemurafenib (PLX4032; RG7204; RO5185426) ist ein erstklassiger, selektiver, potenter Inhibitor der B-RAF-Kinase mit IC50s-Werten von 31 bzw. 48 nM für RAFV600E und c-RAF-1. Vemurafenib induziert die autophagy.
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively. Vemurafenib induces cell autophagy.
For research use only. We do not sell to patients.
Vemurafenib Chemical Structure
CAS No. : 918504-65-1
This product is a controlled substance and not for sale in your territory.
Based on 76 publication(s) in Google Scholar
Other Forms of Vemurafenib:
- Vemurafenib-d5 Get quote
- Vemurafenib-d7 Get quote
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 Jan;39:194-206. [Abstract]
- Western analysis of related proteins expression with or without the treatment of vemurafenib and other treatments. Left: M6 are transfected with PLAUR siRNA and negative control siRNA and incubated for 48 h in presence of 1 μM vemurafenib. Right: A375 are transfected either with Mock or uPAR overexpressing plasmid pQ2-uPAR. After 24 h are seeded at the same density (800 cells/ml) and cultured in the presence of vemurafenib at indicated concentrations for 10 days.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2019 Mar 15;144(6):1379-1390. [Abstract]
- Western blot confirmed increased MAPK pathway activity in NEC-DUE2 cells when compared to NECDUE1. Treatment with Vemurafenib (1 μM), GSK2118436A (100 nM), or GSK1120212 (100 nM) for 4 hours leads to decreased MAPK signaling in NEC-DUE2 cells. Lysates are immunoblotted for the proteins indicated.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Oct;37(43):5719-5734. [Abstract]
- BRAF mutants with in-frame β3-αC loop deletions exhibit a robust but differential inhibitor resistance. Stable fibroblast cells that express individual BRAF mutants with in-frame β3-αC loop deletions are treated with Vemurafenib for 4 h, and p-ERK1/2 is probed by immunoblot and quantified.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Dec 8;10(12). pii: E1950. [Abstract]
- Western analysis of protein expression in cells treatmented with or without PLX4032 or RAD001.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Mol Syst Biol. 2017 Jan; 13(1): 905. [Abstract]
- Western blotting for NGFR-inducible COLO858 cells, NGFRHigh A375 and WM115 cells, and NGFRLow MACSF and MZ7MEL cells, treated for 48 h with 0.2 or 1 μM Vmurafenib or DMSO.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54. [Abstract]
- Western blot analysis of p-ERK, ERK, p-AKT and ERK after 24 h of treatment with Vemurafenib. Levels of p-ERK and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to ERK or AKT and α-tubulin. Representative Western blot panels on the left.
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2017 Jan;95(1):97-108. [Abstract]
- Immunoblotting of phosphorylated and total EGFR,AKT, and ERK1/2 in A375-M6 clones treated or not with 0.5 μMvemurafenib for 24 h. 50 μL/ well loaded. Tubulin detected as loading control. Quantification (right) of phosphorylated protein on total protein, normalized on housekeeper (Tubulin).
-
Vemurafenib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2013 Feb 1;19(3):598-609. [Abstract]
- MEKi decreases PD-L1 expression in BRAFi-resistant cells. A, immunoblot analyses of the activities of ERK1/2 and c-Jun in the K028, M34, and K029 parental lines treated with U0126 (U; 20 μM), PLX4032 (PLX; 10 μM), or the combination of U0126 (20 μM) and PLX4032 (10 μM) for 30 minutes. Cells are treated with DMSO (D) as controls. B, immunoblot example showing decrease in PD-L1 expression in parental M34 cells treated with U0126, PLX4032, or the combination.